ALEXANDER LAZAR to Signal Transduction
This is a "connection" page, showing publications ALEXANDER LAZAR has written about Signal Transduction.
Connection Strength
0.717
-
RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway. Cell Physiol Biochem. 2012; 29(3-4):361-72.
Score: 0.114
-
Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 04 05; 173(2):321-337.e10.
Score: 0.043
-
A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
Score: 0.043
-
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther. 2017 10 03; 18(10):816-826.
Score: 0.042
-
Modeling synovial sarcoma metastasis in the mouse: PI3'-lipid signaling and inflammation. J Exp Med. 2016 12 12; 213(13):2989-3005.
Score: 0.039
-
Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors. Cancer. 2015 Nov 15; 121(22):4088-96.
Score: 0.036
-
Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. Hum Pathol. 2015 Jul; 46(7):1015-26.
Score: 0.035
-
Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol Cancer. 2015 Mar 07; 14:55.
Score: 0.035
-
Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2012 Aug; 11(8):1758-69.
Score: 0.029
-
INK4a/ARF [corrected] inactivation with activation of the NF-?B/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. Cancer Res. 2012 Sep 15; 72(18):4682-95.
Score: 0.029
-
MiR-155 is a liposarcoma oncogene that targets casein kinase-1a and enhances ?-catenin signaling. Cancer Res. 2012 Apr 01; 72(7):1751-62.
Score: 0.028
-
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol. 2012 Feb; 25(2):212-21.
Score: 0.028
-
Clinicopathologic considerations: how can we fine tune our approach to sarcoma? Semin Oncol. 2011 Oct; 38 Suppl 3:S3-18.
Score: 0.028
-
Genetic alterations in signaling pathways in melanoma. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2301s-2307s.
Score: 0.019
-
Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. Cell Rep. 2021 01 26; 34(4):108678.
Score: 0.013
-
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Rep. 2020 10 20; 33(3):108293.
Score: 0.013
-
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019 02 11; 35(2):204-220.e9.
Score: 0.011
-
Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018; 9:2102.
Score: 0.011
-
Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene. 2017 09 21; 36(38):5421-5431.
Score: 0.010
-
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
Score: 0.010
-
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. Clin Cancer Res. 2016 Mar 01; 22(5):1150-60.
Score: 0.009
-
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014 Nov 01; 20(21):5537-46.
Score: 0.008
-
EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J Pathol. 2014 Feb; 232(3):308-18.
Score: 0.008
-
CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 2013 Feb 28; 152(5):1077-90.
Score: 0.008
-
Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res. 2012 Sep 01; 18(17):4633-45.
Score: 0.007
-
New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res. 2012 Mar 01; 18(5):1195-200.
Score: 0.007
-
Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res. 2011 Sep 15; 17(18):5901-12.
Score: 0.007
-
High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma. Genes Chromosomes Cancer. 2011 Nov; 50(11):849-58.
Score: 0.007
-
Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 2011 Jan 27; 30(4):457-70.
Score: 0.006
-
Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer. 2011 Jan 15; 117(2):380-9.
Score: 0.006
-
Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med. 2009 Oct 19; 11:e30.
Score: 0.006
-
Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009 May; 8(5):1157-68.
Score: 0.006
-
Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol. 2008 01; 23(1):117-26.
Score: 0.005
-
Human sebaceous tumors harbor inactivating mutations in LEF1. Nat Med. 2006 Apr; 12(4):395-7.
Score: 0.005
-
Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development. 2005 Jan; 132(2):415-27.
Score: 0.004